Deep Medicine Acquisition EBIT

The latest EBIT for DMAQ is $-11M as of June 2026. That compares with $-3.2M in the prior-year period — down 232.3% year over year. That is below the sector sector average of $-6.4M. Investors often review this figure alongside Deep Medicine Acquisition's historical trend and sector peers before judging valuation or financial health.

Over the past year, DMAQ's EBIT moved from $-3.2M to $-11M — a 232.3% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Deep Medicine Acquisition's operating scale or balance-sheet position.

Against its sector companies, DMAQ currently prints $-11M for EBIT, while the sector average sits near $-6.4M. That is roughly 65.1% below the sector mean. Large gaps often invite a closer look at Deep Medicine Acquisition's growth, margins, and balance sheet.

A EBIT figure of $-11M for DMAQ is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $-6.4M. Explore the charts below for those layers of context.

After noting DMAQ's EBIT ($-11M), review year-over-year change from $-3.2M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.